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Abstract
Background: The IRE1a-XBP1 pathway is a conserved adaptive mediator of the unfolded protein response. The
pathway is indispensable for the development of secretory cells by facilitating protein folding and enhancing
secretory capacity. In the immune system, it is known to function in dendritic cells, plasma cells, and eosinophil
development and differentiation, while its role in T helper cell is unexplored. Here, we investigated the role of the
IRE1a-XBP1 pathway in regulating activation and differentiation of type-2 T helper cell (Th2), a major T helper cell
type involved in allergy, asthma, helminth infection, pregnancy, and tumor immunosuppression.
Methods: We perturbed the IRE1a-XBP1 pathway and interrogated its role in Th2 cell differentiation. We performed
genome-wide transcriptomic analysis of differential gene expression to reveal IRE1a-XBP1 pathway-regulated genes
and predict their biological role. To identify direct target genes of XBP1 and define XBP1’s regulatory network, we
performed XBP1 ChIPmentation (ChIP-seq). We validated our predictions by flow cytometry, ELISA, and qPCR. We
also used a fluorescent ubiquitin cell cycle indicator mouse to demonstrate the role of XBP1 in the cell cycle.
Results: We show that Th2 lymphocytes induce the IRE1a-XBP1 pathway during in vitro and in vivo activation.
Genome-wide transcriptomic analysis of differential gene expression by perturbing the IRE1a-XBP1 pathway reveals
XBP1-controlled genes and biological pathways. Performing XBP1 ChIPmentation (ChIP-seq) and integrating with
transcriptomic data, we identify XBP1-controlled direct target genes and its transcriptional regulatory network. We
observed that the IRE1a-XBP1 pathway controls cytokine secretion and the expression of two Th2 signature
cytokines, IL13 and IL5. We also discovered that the IRE1a-XBP1 pathway facilitates activation-dependent Th2 cell
proliferation by facilitating cell cycle progression through S and G2/M phase.
Conclusions: We confirm and detail the critical role of the IRE1a-XBP1 pathway during Th2 lymphocyte activation
in regulating cytokine expression, secretion, and cell proliferation. Our high-quality genome-wide XBP1 ChIP and
gene expression data provide a rich resource for investigating XBP1-regulated genes. We provide a browsable
online database available at http://data.teichlab.org.
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Background
T helper (Th) cells (CD4+ T cells) are central to the
adaptive immune response and immune tolerance and
potentiate innate immune response pathways [1, 2].
These cells are key players in infections, allergies,
auto-immunity, and anti-tumor immune responses. De-
pending upon the immunogen or allergen (e.g., infection,
commensal microorganism, or self-antigen), naive T
helper cells become activated, proliferate, and are able to
differentiate into several subtypes, such as Th1, Th2,
Th17, and regulatory T cell (Treg). This Th subtype clas-
sification is based on their differential expression of cy-
tokines and key lineage-specific transcription factors [2,
3]. Th2 lymphocytes secrete the characteristic cytokines
IL4, IL5, IL10, and IL13. These secretory cells are in-
volved in worm parasite expulsion, exaggerate allergies
and asthma, potentiate pregnancy [4], and suppress
anti-tumor immunity [5]. Transcription factors that are
involved in differential production and regulation of
cytokine genes, for example GATA3 in Th2, are well
studied. However, cytokine gene expression is only one
aspect of the T helper cell differentiation process. The
ability to rapidly proliferate is another key attribute of T
helper lymphocytes (Fig. 1a), and the full regulatory
circuitry controlling these processes is still incompletely
understood.
Proliferation is required for clonal expansion, which
forms the basis of the adaptive immune response [6, 7].
The Gata3/RuvB-like protein 2 (Ruvbl2) complex was
shown to be a key regulator of Th2 cell proliferation [8],
and several other transcription factors, such as Stat6, are
implicated in the regulatory circuitry controlling T
helper cell proliferation and differentiation. Additional
transcription factors are likely to be involved in regulat-
ing this highly organized, complex process.
At the cell biological level, to synthesize, fold, and se-
crete proteins, including cytokines, activated T helper
cells need to contain a well-differentiated endoplasmic
reticulum (ER) and protein secretory machinery. It is an
open question how activated T helper cells meet this
protein folding and secretory demand. Secretory cells
(e.g., pancreatic β-cell, acinar cells) address this chal-
lenge by upregulating the unfolded protein response
(UPR) pathway triggered by the accumulation of unfolded
proteins in the endoplasmic reticulum (ER) [9–11]. Three
ER membrane-resident sensors, the endonuclease IRE1a
(encoded by ERN1 gene), the kinase PERK, and the cleav-
able precursor of the transcription factor ATF6, coordin-
ate the process. Among these three, the IRE1a-XBP1
pathway is the most evolutionary conserved pathway
(Fig. 1a) [12, 13]. During ER stress, the kinase, IRE1a, oli-
gomerizes, autophosphorylates, and uses its endoribonu-
clease activity to splice a 26-nucleotide fragment from the
unspliced XBP1 mRNA (XBP1u). This then results in the
functional spliced form of the transcription factor XBP1
(XBP1s) [14]. XBP1s regulates the expression of numerous
target genes involved in ER biogenesis. Its role has been
studied in secretory cells, such as pancreatic acinar cells,
plasma cells, and dendritic cells (DCs). In these cell types,
XBP1 occupies chromatin and controls gene expression in
a cell-type-specific manner [15]. This suggests that XBP1
may play a role in diverse cell types. Therefore, we set out
to investigate its specific function in CD4+ T lymphocytes
(Fig. 1a).
The role of the IRE1a-XBP1 pathway in immunity and
inflammation is now emerging [16–20]. The pathway
has been described in dendritic cells, plasma cells, CD8+
T cells, and eosinophil development and differentiation
[21–26]. Interestingly, it has been reported recently that
the pathway causes cancer-associated immune suppres-
sion by causing dendritic cell dysfunction [27]. The
pathway is also involved in alternative activation of mac-
rophages and in obesity [28]. Together, these reports
suggest that the XBP1 transcription factor can contrib-
ute to a wide range of biological processes. IRE1a inhibi-
tors (e.g., 4μ8c) have been proposed as a treatment of
cancer, by reinstating cancer immunity and eosinophilia
by inhibiting eosinophil differentiation [21, 27, 29, 30].
Here, we test the role of the XBP1 transcription factor
in regulating T helper cell activation through inhibition
of the IRE1a-XBP1 pathway by the small molecule in-
hibitor 4μ8c.
Using genome-wide approaches, integrating transcrip-
tomic and XBP1 chromatin occupancy data, we elucidate
the regulatory circuitry governed by the IRE1a-XBP1
pathway in Th2 lymphocytes. We found that the path-
way observed in other cells is conserved in T helper cells
in terms of secretory stress adaptation. Further, we show
that XBP1 regulates genes that control diverse facets of
Th2 cell physiology. In addition to resolving protein
folding and secretory stress, it accelerates cell prolifera-
tion and controls cytokine synthesis and secretion.
Our data provide a rich resource for investigating
XBP1-regulated genes with genome-wide chromatin oc-
cupancy and expression, with a browsable online data-
base at http://data.teichlab.org.
Methods
Materials
CD4+CD62L+ T Cell Isolation Kit II, mouse (Miltenyi Bio-
tec, 130-093-227); Naive CD4+ T Cell Isolation Kit, mouse
(Miltenyi Biotec, 130-104-453); FITC BrdU Flow Kit (BD
Pharmingen, 51-2354AK); LIVE/DEAD™ Fixable Violet
Dead Cell Stain Kit (Molecular probes, L34955); Cell-
Trace™ Violet Cell Proliferation Kit (Molecular probes,
C34571); Mouse IL-13 ELISA Ready-SET-Go Kit
(eBioscience, 88-7137-22); Mouse IL-4 ELISA Ready-SET-
Go Kit (eBioscience, 88-7044-88); Mouse IL-5 ELISA (BD
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Biosciences, 555236); PE Mouse anti-XBP1S Clone
Q3-695 (BD Pharmingen, 562642); XBP1 (M-186)X-
(Santa cruz, Sc 7160x); IL5-PE (BD Pharmingen, 554395);
IL4-APC, Clone 11B11 (eBioscience, 17-7041-82); IL13-
AF488, Clone eBio3A (eBioscience, 53-7133-82); IFNγ-Per
CP Cy5.5, Clone XMG1.2 (eBioscience, 45-7311-82);
FACS Staining buffer (eBioscience, 00-4222-26); IC
Fixation buffer (eBioscience, 00-8222-49); Fixation/
Permeabilization Diluent (eBioscience, 00-5223-56);
Fixation/Permeabilization concentrate (eBioscience, 00-
5123-43); Permeabilization buffer (eBioscience, 00-8333-
56); SV Total RNA Isolation System (Promega, Z3101);
Transcriptor High Fidelity cDNA Synthesis kit (Roche,
05081955001); SYBR™ Select Master Mix (Applied Biosys-
tems, 4472908); Western blot antibodies: IRE1α (14C10)
Rabbit mAb (Cell Signaling, #3294), IRE1 alpha [p Ser724]
Antibody (Novus biologicals,NB100-2323).
Mice
The mice (C57BL/6, IL13-eGFP reporter, IL4-eGFP re-
porter, and FUCCI) were maintained under specific
pathogen-free conditions at the Wellcome Trust Gen-
ome Campus Research Support Facility (Cambridge,
UK) and were used at 6–12 weeks of age. We generated
a transgenic FUCCI mouse, similar to published FUCCI
strain [31].
T helper cell culture
Splenic naive T helper cells were purified with the
CD4+CD62L+T Cell Isolation Kit II (Miltenyi Biotec)
and polarized in vitro toward differentiated Th2 subtype
as described before in [32]. In brief, naive cells were
seeded into anti-CD3e (2 μg/ml, clone 145-2C11,
eBioscience) and anti-CD28 (5 μg/ml, clone 37.51,
eBioscience) antibody coated 96-well round bottom
plates. The medium contained the following cytokines
and/or antibodies for Th2 subtype: recombinant murine
IL-2 (10 ng/ml, R&D Systems), recombinant murine
IL-4 (10 ng/ml, R&D Systems), and neutralizing
anti-IFN-g (5 μg/ml, cloneXMG1.2eBioscience). The
cells were removed from the activation plate on day 4
(72 h). Th2 cells were cultured for another 2 days in the
absence of anti-CD3 and CD28 stimulation. Then, cells
were restimulated by anti-CD3e/CD28-coated plate for
6 h. For flow cytometric detection, cells were treated
with monensin (2 μM, eBioscience) for the last 3 h.
4μ8c treatment
4μ8c (final concentration 15 μM) was added to the cul-
ture media at the beginning of the culture, and with the
fresh culture media when cells were transferred from the
activation plate to the resting plate.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was isolated from two million cells by SV
total RNA isolation kit (Promega). cDNA was prepared
by annealing 500 ng RNA with oligo dT as per the man-
ufacturer’s instructions (Transcriptor High Fidelity
cDNA Synthesis kit, Roche). The cDNA samples were
diluted 10 times with H20. Two microliters of cDNA
was used in 12 μl qPCR reactions with appropriate
primers and SYBR Green PCR Master Mix (Applied Bio-
systems). Experiments were performed at least three
times and data represent mean values ± standard devi-
ation. For XBP1, mRNA was amplified by PCR and
products were separated by electrophoresis through a
2.5% agarose gel and visualized by ethidium bromide
staining. The primer list is provided below:
IL4-F: 5′-AACTCCATGCTTGAAGAAGAACTC-3′
IL4-R: 5′-CCAGGAAGTCTTTCAGTGATGTG-3′
IL13-F: 5′-CCTGGCTCTTGCTTGCCTT-3′
IL13-R: 5′-GGTCTTGTGTGATGTTGCTCA-3′
IL5-F: 5′-GCAATGAGACGATGAGGCTTC-3′
(See figure on previous page.)
Fig. 1 T helper cells upregulate the IRE1a-XBP1 pathway during activation. a Schematic representation of the hypothesis. In this study, we are
asking what role does the IRE1a-XBP1 pathway play during T helper cell activation. T helper cell activation is a dramatic transformation from a
quiescent cell state to a rapidly proliferative and highly protein productive/secretive cellular state. b Overview of the experiment. Splenic naïve T
cells were purified by negative selection and activated in anti-CD3e/C28 antibody-coated plates under Th2 differentiation conditions (i.e., in the
presence of anti-IFNγ neutralizing antibody, IL2, and IL4) for 72 h, rested for 42 h, and restimulated on anti-CD3e/CD28 antibody-coated plate.
Restimulated Th2 cells were used in RNA sequencing, ChIPmentation (ChIP sequencing), Western blot, qPCR, and flow cytometry. To perturb
IRE1a-XBP1 pathway, we used 15-μM 4μ8c that specifically blocks the pathway by inhibiting IRE1a endonuclease activity. The drug was added to
the culture media at the beginning of the culture and during passage from the activation plate to the resting plate. c Naïve T helper cells and in
vitro differentiated Th2 lymphocytes were analyzed for IRE1a mRNA expression by qRT-PCR (left panel), protein expression by Western blot
(middle panel), and phosphorylated IRE1a (P-IRE1a) by Western blot (right panel). The density of Western blot bands from five independent
experiments of IRE1a and three independent experiments of phospho-IRE1a were measured and displayed on top of each Western blot panel.
d Naïve T cells were cultured under Th2 differentiation conditions in the presence or absence of IRE1a inhibitor (4μ8c). In vitro reactivated Th2
lymphocytes were analyzed by RT-PCR using a pair of primers that discriminate the cDNA derived from spliced and unspliced form of XBP1
mRNA. Tunicamycin-treated Th2 cells were used as a positive control. e Naïve T helper cells (N) and in vitro differentiated and restimulated Th2
cells (differentiated in the presence or absence of 4μ8c) were stained with fluorescent dye-conjugated anti-XBP1s-specific antibody and analyzed
by flow cytometry. Gating: singlets > live cells > XBP1s. One representative FACS profile is displayed (left panel), and the graph containing all
results (n = 5) is shown in the “right panel”. Tunicamycin-treated Th2 cells were used as a positive control
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IL5-R: 5′-CCCCTGAAAGATTTCTCCAATG-3′
ERN1-F: 5′-ACACCGACCACCGTATCTCA-3′
ERN1-R: 5′-CTCAGGATAATGGTAGCCATGTC-3′
XBP1-F: 5′-ACACGCTTGGGAATGGACAC-3′
XBP1-R: 5′-CCATGGGAAGATGTTCTGGG-3′
RPLP0-F: 5′-CACTGGTCTAGGACCCGAGAA-3′
RPLP0-R: 5′-GGTGCCTCTGGAGATTTTCG-3′
XBP1s-F: 5′-ACACGCTTGGGAATGGACAC-3′
XBP1s-R: 5′-GTGTCAGAGTCCATGGGA-3′
ELISA
IL13, IL4, and IL5 concentration in the Th2 culture su-
pernatants were quantified using ELISA kit following the
manufacturer’s instruction (see the “Materials” section
for the kit specification).
Flow cytometry
In worm infection mouse experiments, splenocytes were
prepared on day 7 post-infection from Nippostrongylus
brasiliensis infected or control uninfected mice, stained
with anti-CD3e, anti-CD4 (eBioscience), and XBP1s-PE
(BD Pharmingen) antibodies following the mouse regula-
tory T cell staining kit protocol (eBioscience), and were
measured by flow cytometry on a Fortessa (BD Biosci-
ences) using FACSDiva. The data were analyzed by the
FlowJo software. For in vitro Th cell experiments, stain-
ing was performed following eBioscience intracellular
staining protocol for cytokines and nuclear staining/
transcription factor staining protocol for XBP1 tran-
scription factor using eBioscience reagents and kit
protocol. The following antibodies were fluorescent
dye-conjugated primary antibodies: IL-4, IL-13, IL-5,
CD4 and IFNγ (eBioscience), and XBP1s (BD Pharmin-
gen). Stained cells were analyzed on a Fortessa (BD
Biosciences) using FACSDiva and FlowJo software.
CompBeads (BD Biosciences) were used for compensa-
tion where distinct positively stained populations were
unavailable.
Cell proliferation assay
Naive Th cells were stained with CellTrace Violet
following the CellTrace Violet Cell Proliferation Kit
(Invitrogen) protocol and cultured under activation-
differentiation conditions for Th2 as described previ-
ously, in the presence or absence of 15 μM 4μ8c for
4 days. Flow cytometry was performed using a BD For-
tessa and data analysis with FlowJo software.
N. brasiliensis infection and splenocyte preparation
C57BL/6 female mice were subcutaneously injected with
100 μl (300/500 live third stage N. brasiliensis larvae per
dose). Spleen was taken from infected mice 7 days after
infection. Cells were isolated from spleen by smashing
the tissue through a 70-μm cell strainer and suspended
in RBC lysis buffer (eBioscience). Single-cell suspensions
of splenocytes were then stained following FACS stain-
ing protocol.
Analysis of bulk RNA-sequencing data
For each sample, reads were mapped to the Mus muscu-
lus genome (GRCm38) using GSNAP with default pa-
rameters [33]. Uniquely mapped reads to the genome
were counted using htseq-count (http://htseq.readthe-
docs.io/) and normalized with size factors calculated by
DESeq2 [34]. Differentially expressed genes across con-
ditions were identified using DESeq2 with an adjusted p
value cutoff < 0.05.
XBP1 ChIPmentation
In vitro differentiated and reactivated Th2 cells were
used in ChIP. Two independent biological replicates
were performed. Twenty million cells from each sample
were crosslinked in 1% HCHO (prepared in 1X DPBS)
at room temperature for 10 min, and HCHO was
quenched by the addition of glycine at a final concentra-
tion of 0.125 M. Cells were pelleted at 4 °C at 2000×g,
washed with ice-cold 1X DPBS twice, and snapped
frozen in liquid nitrogen. The cell pellets were stored in
− 80 °C until the experiments were performed. ChIP-
mentation was performed according to the version 1.0 of
the published protocol [35] with some modifications at
the ChIP stage.
Briefly, cell pellets were thawed on ice and lysed in
300 μl ChIP Lysis Buffer I (50 mM HEPES.KOH, pH 7.5,
140 mM NaCl, 1 mM EDTA, pH 8.0, 10% Glycerol, 0.5%
NP-40, 0.25% Triton X-100) on ice for 10 min. Then,
cells were pelleted at 4 °C at 2000×g for 5 min, washed
by 300 μl ChIP Lysis Buffer II (10 mM Tris-Cl, pH 8.0,
200 mM NaCl, 1 mM EDTA, pH 8.0, 0.5 mM EGTA,
pH 8.0), and pelleted again at 4 °C at 2000×g for 5 min.
Nuclei were resuspended in 300 μl ChIP Lysis Buffer III
(10 mM Tris-Cl, pH 8.0, 100 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5% N-laur-
oylsarcosine). Chromatin was sonicated using Bioruptor
Pico (Diagenode) with 30 s ON/30 s OFF for 3 cycles.
Thirty microliter 10% Triton X-100 were added into
each sonicated chromatin, and insoluble chromatin was
pelleted at 16,100×g at 4 °C for 10 min. One microliter
supernatant was taken as input control. The rest of the
supernatant was incubated with 10 μl Protein A Dyna-
beads (Invitrogen) pre-bound with 1 μg XBP1 antibody
(XBP1 (M-186)X - Santa cruz), in a rotating platform in
a cold room overnight. Each immunoprecipitation (IP)
was washed with 500 μl RIPA Buffer (50 mM HEPES.-
KOH, pH 7.5, 500 mM LiCl, 1 mM EDTA, 1% NP-40,
0.7% Sodium Deoxycholate, check components) for
three times. Then, each IP was washed with 500 μl
10 mM Tris, pH 8.0 twice, and resuspended in 30 μl
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tagmentation reaction mix (10 mM Tris.Cl, pH 8.0,
5 mM Mg2Cl, 1 μl TDE1 (Nextera)). Then, the tagmen-
tation reaction was put on a thermomixer at 37 °C for
10 min at 800 rpm shaking. After the tagmentation reac-
tion, each IP was washed sequentially with 500 μl RIPA
Buffer twice, and 1X TE NaCl (10 mM Tris.Cl, pH 8.0,
1 mM EDTA, pH 8.0, 50 mM NaCl) once. Elution and
reverse crosslinking was done by resuspending the beads
with 100 μl ChIP Elution Buffer (50 mM Tris.Cl, pH 8.0,
10 mM EDTA, pH 8.0, 1% SDS) on a thermomixer at
65 °C overnight, 1400 rpm. DNA was purified by MinE-
lute PCR Purification Kit (QIAGEN, cat no. 28004) and
eluted in 12.5 μl Buffer EB (QIAGEN kit, cat no 28004),
which yielded ~ 10 μl ChIPed DNA.
The library preparation reactions contained the
following:
Ten-microliter purified DNA (from above), 2.5-μl PCR
Primer Cocktails (Nextera DNA Library Preparation Kit,
Illumina Cat no. FC-121-1030), 2.5 μl N5xx (Nextera
Index Kit, Illumina cat no. FC-121-1012), 2.5 μl N7xx
(Nextera Index Kit, Illumina cat no. FC-121-1012),
7.5 μl NPM PCR Master Mix (Nextera DNA Library
Preparation Kit, Illumina cat no. FC-121-1030). PCR was
set up as follows: 72 °C, 5 min; 98 °C, 2 min; [98 °C,
10 s, 63 °C, 30 s, 72 °C, 20 s] × 12; 10 °C hold. The amp-
lified libraries were purified by double AmpureXP beads
purification: first with 0.5X bead ratio, keep supernatant,
second with 1.4X bead ratio, keep bound DNA. Elution
was done in 20 μl Buffer EB (QIAGEN). One microliter
of library was run on an Agilent Bioanalyzer to see the
size distribution. Sequencing was done on an Illumina
Hiseq2000 platform using the v4 chemistry (75 bp PE).
ChIPmentation analysis
The reads were first trimmed using Trimmomatic 0.3664
with settings ILLUMINACLIP:NexteraPE-PE.fa:2:30:10
LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MIN
LEN:30. Peaks were then called using MACS265, merged
over time, and annotated using HOMER66.
The quality of the peaks was assessed using the two
available replicates of XBP1.
Inferred regulatory cascade of XBP1
Transcription factors were obtained from the Ani-
malTFDB 2.0 [36] and were defined as targets of XBP1 if
they were intersected by a ChIPmentation peak and
differentially expressed between Th2 (control) and
4μ8c-treated Th2. Genes were defined as targeted by
these transcription factors if in the STRING version 10
database [37], they had an “expression” mode of inter-
action with a score greater than 200 with these tran-
scription factors in mouse, and were differentially
expressed between Th2 (control) and 4μ8c-treated Th2.
XBP1s overexpression and comparison with drug
treatment
XBP1s cloning
To generate an pMSCV-XBP1s-IRES-mCherry con-
struct, Flag-XBP1s was amplified from Flag-XBP1s-
pcDNA5/FRT/TO (gift from Prof. David Ron) by PCR (F
primer: cgccggaattcagatcttacgtagctagcgCAAATGGACTA
CAAAGACGA, R primer: gcggaattgatcccgctcgagcaattgg
TTAGACACTAATCAGCTGGG). This Flag-XBP1s
fragment was integrated with pMSCV-IRES-mCherry
fragment of pMSCV-IRES-mCherry FP (Addgene
#52114, gift from prof. Dario Vignali) cut by bamHI.
Viral transduction
Virus was produced following the procedure as de-
scribed in our previous publication (Henriksson et al.
2017, doi: https://doi.org/10.1101/196022). Briefly, platE
cells were grown in Advanced DMEM with FBS,
pen-strep (PS) and L-glutamine. A mix of 1-μg pCL-Eco
(Addgene #12371, gift from Inder Verma, [38]), 1-μg
retroviral plasmid, and 2-μl PLUS were mixed in 0.5 ml
OptiMEM. The mix was vortexed and incubated for
2 min at room temperature. Six-microliter Lipofectamin
LTX was added; the mix pipetted up and down and in-
cubated for 30 min at room temperature. The mix was
added to one well of a six-well plate, containing 80–90%
cells and freshly replaced 1.5-ml OptiMEM. Five hours
later, the media was replaced with 2-ml Advanced
DMEM. The morning after the media was again re-
placed with 1.5-ml Advanced DMEM. Forty-eight hours
after this replacement, the virus was harvested. The
supernatant was filtered by centrifugation (1000g, 4 °C,
10 min) and stored at 4 °C overnight.
Naive CD4+ T cells were purified by negative selection
using MACS as described above and plated on
anti-CD3/CD28-coated plates under Th2 differentiation
condition with or without 15 μM 4μ8c on the same day
as the virus harvest. The next day, 40-μl IMDM +
160-μl virus supernatant was added into each well of a
96-well plate (round-bottom). To this mix, we added
55 μM βME (2-ME), 8 μg/ml polybrene, and 10 ng/ml
IL4 and IL2. The cells were spun in a centrifuge for
1.5 h at 1100g at 32 °C. The cells were kept for another
3 h in an incubator at 32 °C. The cells were then kept at
37 °C overnight. The next morning, the media was re-
placed with fresh IMDM supplemented with IL4, βME,
and 15 μM 4μ8c (or DMSO).
For RNA sequencing: 5 days after T cell activation,
5000 fluorescent (transduced) cells were FACS-sorted
into 20-μl RLT buffer and frozen in − 80 °C. The RNA
was extracted using 30 μl SPRI beads and eluted into
5-μl media of the following composition: 2 μl dNTP
(10 μM), 2 μl Oligo-dT (100 μM), and 1 μl nuclease-free
water. Four microliters of the elute was used as input
Pramanik et al. Genome Medicine           (2018) 10:76 Page 6 of 19
into smart-seq 2 [39]. Pre-amplification was done using
8 PCR cycles. Library preparation was done using Nex-
tera XT at 1/4 of the manufacturer-specified reaction
size. The libraries were sequenced on an Illumina HiSeq
2500 50SE. The raw reads are deposited at ArrayExpres-
sion (E-MTAB-7104).
Reads were trimmed using Trimmomatic 0.36 using set-
tings -phred33 ILLUMINACLIP:NexteraPE-PE.fa:2:30:10
LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MIN-
LEN:30. Reads were mapped using Kallisto 0.44.0 with
settings -b 100 --single -l 180 -s 20. A custom R script col-
lected the estimated counts into a total count matrix.
Differential expression analysis was performed using
DESeq2. The control cells were compared to 4μ8c
treated, with XBP1s overexpression, and with simultan-
eous 4μ8c treatment and overexpression. The heatmap
shows the fold change of genes that in any comparison
has an adjusted p value of 10−10. Other cut-offs yield
similar results.
For cell proliferation assays, naïve cells were stained
with CellTrace Violet following the protocol as described
above.
For intracellular cytokine IL5 and IL13 detection,
XBP1s- or empty vector-transduced cells were sorted by
cell sorter (as described above for RNAseq), rested for
two more days to propagate, and reactivated in CD3e/
CD28-coated plates for 6 h. The cells were then stained
with fixable live-dead dye, fluorescent dye-conjugated
anti-IL13 and IL5 antibodies, and analyzed by FACS.
Results and discussion
In this study, to understand the role of IRE1a-XBP1
pathway, our basic strategy was to use an in vitro Th2
differentiation model (Fig. 1b). Naïve T helper cells were
activated by TCR activation in anti-CD3e/CD28-coated
plates under Th2 differentiation condition for 72 h,
rested for 42 h, and restimulated by TCR activation
using anti-CD3e/CD28-coated plates. To perturb
IRE1a-XBP1 pathway, we used a well-established drug
4μ8c that specifically blocks the pathway by inhibiting
IRE1a endonuclease activity [40]. The drug was added to
the culture media at 15-μM concentration at the
beginning of the culture and during passage from the
activation plate to the resting plate. The choice of drug
concentration was determined by its highest IRE1a
inhibition efficiency with lowest cell toxicity
(Additional file 1: Figure S1). We compared transcrip-
tomes of naïve and restimulated Th2 (drug treated and
untreated) lymphocytes by RNA sequencing, identified
XBP1 transcription factor binding sites in reactivated
Th2 by ChIPmentation (ChIP-sequencing), and inte-
grated the genome-wide data to predict direct targets
and their regulatory role.
T helper cells switch on the IRE1a-XBP1 pathway during
in vitro activation
Activated and differentiated T helper cells secrete an
abundance of cytokines. Therefore, a well-developed
secretory machinery is a prerequisite for cells to adapt to
this secretory stress. To predict the involvement of
ER-stress/UPR pathway during T helper cell activation, we
compared transcriptome of naïve and differentiated Th2
cells (restimulated Th2). Differentially expressed genes as
obtained from this comparison were integrated in the
“Protein Processing in the Endoplasmic Reticulum”
KEGG pathway to visualize the components that are
up- or downregulated. The analysis shows that when
naïve T helper cells are activated and differentiated
into Th2 cells, they upregulate expression of genes in-
volved in the ER stress pathway (Additional file 1:
Figure S2). Several factors that have previously been
characterized as controllers of protein folding and se-
cretion, including XBP1 itself, are upregulated during
T helper cell differentiation.
To validate this prediction, and specifically investigate
the involvement of the IRE1a-XBP1 pathway, we mea-
sured IRE1a mRNA and protein expression in Th2 lym-
phocytes differentiated and reactivated in vitro (Fig. 1b).
The cells were analyzed by qPCR and Western blot to
compare the mRNA and protein respectively. We found
that both mRNA and protein level were upregulated in
activated T helper cells (Fig. 1c, left and middle panel).
It is known that phosphorylation of IRE1a denotes its
functional state. We observed that the protein is phos-
phorylated in activated Th2 lymphocytes (Fig. 1c, right
panel). This increased phospho-IRE1a can be explained
by the increased synthesis of the protein, though we can-
not exclude the possibility of increased kinase activity
and auto-phosphorylation. The densitometric analysis
of Western blot band suggests that both mechanisms,
upregulation of protein synthesis and increased phos-
phorylation, are involved. Protein upregulation in-
creased threefold, but the phospho-protein increased
4.5-fold (Fig. 1c).
Activated IRE1a splices the unspliced XBP1 (XBP1u)
mRNA and produces a spliced XBP1 (XBP1s) mRNA
isoform. We observed increases in the spliced form of
XBP1 (XBP1s), both at mRNA and protein levels, upon
T helper cell activation (Fig. 1d, e). Tunicamycin was
used as a positive control. It is a drug that inhibits
N-linked glycosylation and thereby causes accumulation
of unfolded proteins (i.e., endoplasmic reticulum (ER)
stress), and increases XBP1s by enhancing IRE1a activity.
Specific inhibition of the IRE1a endonuclease activity by
treating the cells with 4μ8c [40] abolished both the
XBP1s mRNA and protein isoforms, confirming that the
formation of the spliced form was dependent on IRE1a
activity (Fig. 1d, e).
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These results confirm that the IRE1a-XBP1 pathway is
conserved in Th2 lymphocytes and upregulated during
in vitro T helper cell activation. Next, we set out to in-
vestigate whether this also holds in vivo.
In vivo activated T helper cells upregulate the IRE1a-XBP1
pathway
To test whether the IRE1a-XBP1 pathway is operational
in CD4+ T cells in vivo, we infected C57BL/6 mice with
the helminth parasite Nippostrongylus brasiliensis, a
well-established model of Th2-driven immune responses
[32, 41, 42]. After 7 days post-infection, we analyzed
XBP1s protein expression in T helper cells by flow cy-
tometry. We found T helper cells from worm-infected
mice express significantly more XBP1s compared to un-
infected control mice, suggesting an upregulation of the
pathway (Fig. 2).
These results confirm that the pathway is active in
vivo. Therefore, we set out to dissect the pathway using
genome-wide approaches in Th2 lymphocytes.
Genome-wide transcriptomic analysis of differential gene
expression reveals IRE1a-XBP1-regulated genes
To capture a global gene regulatory role of the IRE1a-
XBP1 pathway, we compared in vitro activated Th2 cells
to cells with inhibited IRE1a endonuclease activity by
adding 4μ8c into the cell culture media. We then com-
pared the transcriptomes of activated Th2 lymphocytes
with or without inhibition of the IRE1a-XBP1 pathway.
Transcriptomes of 4μ8c-treated and untreated Th2 cells
were obtained by mRNA sequencing (RNA-seq). Quality
control of the RNA sequencing data is shown in
Additional file 1: Figure S3. Comparing transcriptomes
of naïve and activated Th2 lymphocytes, we found that
10995 genes were differentially regulated upon Th2 acti-
vation. Inhibition of the IRE1a-XBP1 pathway by 4μ8c
treatment resulted in differential expression of 3144
genes as compared to the untreated Th2 control (Fig. 3a,
Additional file 1: Figure S3 right panel). Two thousand
six hundred seventy of these genes were involved in Th2
differentiation (Fig. 3a). Hierarchical clustering of the
genes reveals the groups of genes up- and downregu-
lated upon 4μ8c treatment (Additional file 1: Figure S3,
right). Detailed examination of these genes revealed
many to be associated with the unfolded protein re-
sponse and ER-stress, indicating a major impact of the
IRE1a-XBP1 pathway (Fig. 3b) on these biological pro-
cesses. The complete list of differentially expressed genes
can be found in Additional file 2: Table S1. Gene Ontol-
ogy (GO) analysis of these differentially expressed genes
upon 4μ8c treatment to Th2 cells (i.e., IRE1a-XBP1 path-
way regulated genes) showed that they are enriched in the
following biological processes: “Response to ER stress”
(GO:0006950), “Regulation of signal transduction” (GO:
0009966), “Cytokine production” (GO:0001816), “cell pro-
liferation” (GO:0008283), “cell cycle” (GO:0007049), and
Immune response (GO:0006955) (Fig. 3c). These changes
in the gene expression patterns upon IRE1a inhibition
suggest extensive involvement of XBP1 transcription fac-
tor in Th2 activation and proliferation, as well as
Fig. 2 T helper cells upregulate IRE1a-XBP1 pathway in vivo during infection. Splenocytes from nematode (Nippostrongylus brasiliensis)-infected
mouse (7 days post-infection) were stained with a PE-conjugated anti-XBP1s antibody and analyzed by flow cytometry (gating strategy: singlet >
live cells > CD4+CD3e+ > XBP1s+). One representative FACS profile is displayed (left panel), and the graph containing all results (n = 4) is shown in
the “right panel”
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differentiation. Therefore, we set out to find the
genome-wide chromatin occupancy patterns of the XBP1
transcription factor.
XBP1 ChIPmentation reveals XBP1 direct target genes in
Th2 cells
To identify the genome-wide chromatin occupancy of
XBP1, we performed ChIPmentation, a recently devel-
oped method that has been shown to be faster, more
sensitive, and robust than traditional ChIP-seq ap-
proaches [35], using a ChIP-grade antibody against
XBP1. In vitro differentiated and reactivated Th2 cells
were used for the XBP1 ChIP. Two independent bio-
logical replicates were performed. We obtained 19.3 mil-
lion and 22.4 million pair-end reads for each replicate
respectively. Using MACS2 [43] with a q value less than
0.01 and fold enrichment over 5, we identified 9031 and
7662 peaks, respectively, in the two replicates. Overlap-
ping analysis using bedtools [44] suggested 5892 peaks
were present in both replicates. Therefore, we only fo-
cused on these 5892 peaks for the downstream analysis.
As expected, binding peaks were identified around
promoter regions in known XBP1 target genes, such as
Hspa5 that encodes ER-chaperone protein BiP also
known as Grp78; a binding event was also observed
around the promoter of XBP1 itself (Fig. 4a), indicating
potential auto-regulation of XBP1. To find out the gen-
omic features associated with the XBP1 binding sites, we
compared its peak location to the RefSeq genes using
HOMER [40]. The majority of the XBP1 binding peaks
were located within promoter (defined as upstream
1000 bp and downstream 500 bp relative to annotated
transcriptional start sites) (36%) and intronic (35%) re-
gions, and distal intergenic binding event (25%) were
also frequently observed (Fig. 4b). The genomic distribu-
tion of XBP1 peaks indicates that it binds both pro-
moters and potential enhancers.
To further characterize the XBP1 regulome, we per-
formed de novo motif discovery using HOMER [45] to
identify enriched DNA motifs within XBP1 binding re-
gions. The top motif identified is the consensus sequence
GCCACGT, which is almost identical to the human XBP1
binding motif defined in breast cancer cell lines (Fig. 4c)
[46]. This indicates highly conserved binding specificities
of XBP1 between human and mouse and across cell types.
The top motif enriched in our mouse data also resembles
the XBP1 motif from the JASPAR database [47], again
supporting the high quality of our ChIPmentation data.
The second most enriched motif is the NF-Y binding
motif (Additional file 1: Figure S4C). Interestingly, the
NF-Y motif has been frequently found around promoter
regions of cell cycle genes, especially genes involved in
G2/M cell cycle regulation [48, 49]. Both the XBP1 motif
and the NF-Y motif co-occur around a subset of 258
XBP1 binding peaks (Fig. 4d), indicating potential cooper-
ation between XBP1 and NF-Y transcription factors to
regulate a subset of target genes. The list of target genes
that are potentially co-regulated by XBP1 and NF-Y is
displayed in Additional file 3: Table S2, and a complete list
of XBP1 targets is also provided in Additional file 3: Table
S2. The top five enriched motifs are displayed in
Additional file 1: Figure S4C. To investigate the functions
of XBP1-bound genes, we used GREAT [50] to
characterize XBP1 binding peaks. Most of the significant
GO terms are related to protein folding and ER-stress
(Fig. 4e), which is consistent with the known biological
role of XBP1.
Altogether, the ChIPmentation experiments predict a
role of XBP1 in enhancing protein folding and secretion,
as well as activation of Th2 lymphocytes.
Integration of transcriptomic data and ChIP-seq data to
unravel the XBP1-controlled gene regulatory network
To reveal the XBP1-regulated direct target genes and its
transcriptional regulatory network, we integrated the
genome-wide transcriptomic data and ChIPmentation
data. A direct target gene is defined by its differential ex-
pression upon IRE1a inhibition (i.e., 4μ8c treatment) and
XBP1 transcription factor occupancy at the gene locus.
We found 1143 direct target genes in Th2, of which 122
targets were previously reported as XBP1 direct target in
other cell types (i.e., muscle, pancreatic β-cell, and
plasma cell) (Fig. 5a). In this context, 1021 genes can be
considered as Th2-specific. XBP1 action over its direct
targets has no defined direction, containing genes up-
and downregulated. The top 38 genes following either of
these patterns are shown in Fig. 5b, and the complete
list can be found in Additional file 4: Table S3. The most
(See figure on previous page.)
Fig. 3 Differential gene expression in Th2 due to the inhibition of IRE1a-XBP1 by 4μ8c. Naïve T helper cells were activated under Th2 differentiation
conditions in the presence or absence of 4μ8c. Cells were activated in anti-CD3e and anti-CD28 antibody-coated plates for 3 days, rested for 2 days,
and reactivated in coated plates for 6 h. The RNAseq data were analyzed for differential gene expression. a Venn diagram showing the numbers of
differentially expressed genes in different experimental conditions. “Naïve→ Th2” indicates the differentially expressed genes between naïve T helpers
and Th2 cells. “Th2 → Th2+4μ8c” indicates the differentially expressed genes between untreated and 4μ8c-treated Th2. b Heatmap showing
differentially expressed genes that are well known to be involved in resolution of ER stress imposed by unfolded protein response. The
heatmap shows scaled expression values denoted as row Z-score, in red-blue color scale with red indicating increased expression and blue
indicating decreased expression. c Gene ontology (GO) analysis of the differentially expressed genes between Th2 and 4μ8c-treated Th2
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significant identified biological process and pathways are
related to protein folding and ER-stress (Additional file 1:
Figure S5), which are consistent with its known bio-
logical roles, and also include novel Th2-specific targets.
Despite the preponderance of XBP1’s role in control-
ling this pathway, other transcription factors are also
found to be involved. To examine the regulatory cascade
that follows XBP1 regulation, we built a transcriptional
regulatory network by extracting annotated transcription
factors with promoter or exonic/intronic ChIP-seq peaks
(Fig. 5c). The complete list of the transcription factors
can be found in the Additional file 5: Table S4. This net-
work was further complemented by adding differentially
expressed genes that have annotated interactions with
the target transcription factors in the STRING database
[37] (Additional file 6: Table S5).
The transcription factors that are directly regulated
by XBP1 can be categorized into three broad func-
tional categories involved in the following: resolution
of protein secretory ER stress, regulation of cell cycle
and proliferation, and controlling effector immune
cell function. The ER-stress involved transcription fac-
tors are likely to facilitate cytokine secretion in Th2
lymphocyte. This prediction is based on the previous
reports from secretory cells such as pancreatic acinar
cells and plasma cells. These transcription factors,
namely Bhlha15, Atf3, Atf6, Atf6b, Atf4, and Creb3l2,
have been shown to be involved in secretory stress
adaptation of the ER [9, 15, 51, 52].
The purpose of cell proliferation and cell cycle-related
transcription factors could be to facilitate the controlled
rapid expansion of activated Th2 cells. The immune
response-related factors are likely involved in Th2 differ-
entiation and cytokine production. Therefore, we wanted
to test the effect of XBP1s downregulation in cytokine
secretion, cell proliferation, and cytokine production.
The IRE1a-XBP1 pathway controls cytokine secretion in T
helper cells
The genome-wide comparison of XBP1s-regulated genes
predicts that the factor is involved in secretion of cyto-
kines. To validate this prediction, we blocked IRE1a
endonuclease activity in Th2 cells and analyzed the cell
culture supernatant to quantify the IL4 level by ELISA.
We selected IL4 as a testable candidate cytokine because
its mRNA and protein are unchanged by downregulation
of XBP1 (Additional file 1: Figure S6A left panel, Fig. 6
left and middle panel of top row). We found that the se-
cretion of IL4 is significantly inhibited in 4μ8c-treated
cells (Fig. 6, right panel of top row). As expected, this re-
sult supports the involvement of the IRE1a-XBP1 path-
way in facilitating cytokine secretion in Th2 cells as
predicted. The inhibition of the pathway during restimu-
lation phase has no significant inhibitory effect on IL4
secretion (Additional file 1: Figure S6B). This result sug-
gests that the XBP1s is required during Th2 differenti-
ation, possibly for the development of an efficient
secretory machinery.
The IRE1a-XBP1 pathway controls IL13 and IL5 cytokine
expression
IL5 and IL13 are two prominent type 2 cytokines that
are involved in eosinophilia, allergies and helminth in-
fection. We found that inhibition of IRE1a-XBP1 path-
way significantly suppresses the IL5 and IL13 protein
expression and secretion into the culture medium (Fig. 6
right panels of middle and bottom row). Bioinformatics
analysis of the Th2 transcriptome predicts that the
IRE1a-XBP1 pathway positively controls IL5 and IL13
gene expression, because both the genes were identi-
fied as differentially expressed genes upon IRE1a in-
hibition (Additional file 2: Table S1). We validated
this prediction by RT-qPCR-mediated gene expression
analysis (Additional file 1: Figure S6A, middle and
right panel) and flow cytometry (Fig. 6). These results
suggest a transcriptional involvement of the pathway
regulating IL5 and IL13. Notably, the IL4 mRNA and
protein levels are not affected indicating specific regu-
lation of IL5 and IL13.
IRE1a-XBP1 pathway facilitates activation-dependent T
helper cell proliferation
Cell proliferation rate is a resultant outcome of positive
and negative regulators’ interaction. We observed that
genes encoding both positive and negative regulators of
cell proliferation genes are differentially expressed when
the IRE1a-XBP1 pathway was blocked by 4μ8c (Fig. 7a,
left panel, Additional file 7: Table S6), of which many
genes were found to be direct targets of XBP1 (Fig. 7a,
right panel, Additional file 8: Table S7). This observation
predicts a change in proliferation rate upon IRE1a inhib-
ition. Therefore, we were interested in checking the
(See figure on previous page.)
Fig. 4 Genome-wide chromatin occupancy of XBP1 transcription factor in Th2 lymphocyte. XBP1 ChIPmentation was performed in in vitro
differentiated Th2 cells to obtain genome-wide XBP1 chromatin occupancy. a Snapshot of XBP1 binding peaks around indicated representative
genes from the UCSC genome browser. b Genomic distribution of XBP1 binding peaks. The sector corresponding to the promoter includes
sequences up to 1 kb upstream and 100 bp downstream from the TSS. c Comparing the XBP1 motifs from the JASPAR database (top), ChIP-seq
of the human breast cancer cell lines (middle), and mouse Th2 lymphocytes (bottom). d Motif frequencies of XPB1 and NF-Y around the binding
peaks of XBP1. e Biological processes’ GO terms enriched within XBP1 binding peaks analyzed by GREAT
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Fig. 5 Integration of ChIPmentation and RNA-seq data reveals XBP1 direct target genes and its regulatory network. a Venn diagram comparing
previously reported XBP1 target genes of other secretory cell types with the Th2 direct target genes of this study. XBP1 direct target genes of this
study are those that are common in both “XBP1-occupied genes in Th2” and “Differentially expressed genes (Th2→ Th2+4μ8c)” categories. The
XBP1 direct target genes of B cell/plasma cell, skeletal muscle cells, and pancreatic β-cells were as observed by Acosta-Alvear et al. [17] and have
been used here for comparison. b Heatmap showing the pattern of XBP1 direct target gene expression. The top 38 genes that follow a distinct
pattern have been displayed. c Transcriptional regulatory network: transcription factors that are direct target of XBP1. The genes in the network
are differentially expressed (upregulated—red; downregulated—blue) up on 4μ8c treatment. The transcription factors that are not differentially
expressed but have a XBP1 ChIPseq peak are shown in the right-hand side list
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effect of IRE1a-XBP1 inhibition on cell proliferation. We
performed cell proliferation assay using Th2 cells. Naïve
splenic CD4+ T cell were labeled with CellTrace violet
and activated under Th2 differentiation condition in the
presence or absence of 4μ8c. The fluorescent dye decay
was monitored by flow cytometry. We found that
downregulation of XBP1s inhibits cell proliferation
significantly (Fig. 7b), but does not induce cell death
(Additional file 1: Figure S7).
T helper cell proliferation is associated with differenti-
ation and cytokine production. The reduced IL5 and
IL13 expression (Fig. 6) could potentially be explained
by the fact that cell proliferation is retarded. However, if
reduced proliferation was the primary reason for lack of
secretion, IL4 production would also be inhibited. Yet,
we observed no significant change in IL4 expression
upon IRE1a inhibition (Fig. 6, Additional file 1: Figure
S6A). To examine this discrepancy further, we per-
formed cell proliferation assays using IL13-GFP and
IL4-GFP reporter mouse lines. In IL4-GFP expressing
Th2 cells, we observed an inhibition of IL4 production
in the first few generations of cell division up to 72 h
upon 4μ8c treatment (Additional file 1: Figure S8). But
at 96 h, the difference in IL4 expression becomes insig-
nificant regardless of which generation of cell division
the cells are in. This observation suggests that the re-
tardation of proliferation due to the IRE1a inhibition is
not sufficient to inhibit IL4 expression. In contrast, in
Fig. 6 IRE1a-XBP1 pathway is required for cytokine expression and secretion in Th2 lymphocyte. Naïve T helper cells were cultured following Th2
activation condition in the presence of IRE1a inhibitor 4μ8c for 3 days, rested for 2 days, reactivated by coated plate, and analyzed by flow
cytometry to detect intra-cellular cytokines IL4, IL5, and IL13 expression. Representative FACS profiles are displayed in the first two columns. The
intra-cellular cytokine expression is compared in column 3, with three to seven independent biological replicates. Fourth column: cell culture
supernatants from 4μ8c-treated or DMSO-treated Th2 were analyzed by ELISA to measure the cytokine concentration. FACS gating: lymphocytes
> singlets > live cells > cytokines
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Fig. 7 IRE1a-XBP1 pathway promotes activation-dependent Th2 cell proliferation and cell cycling. a Left panel: hierarchical clustering of
differentially expressed cell proliferation-associated genes in the 4μ8c-treated and untreated Th2 transcriptome. Right panel: hierarchical
clustering of XBP1 direct target genes that are known to be involved in cell proliferation. The heatmap shows scaled expression values
denoted as row Z-score, in red-blue color scale with red indicating increased expression and blue indicating decreased expression. b
Splenic naïve T helper cells were stained with CellTrace Violet dye and activated for 72 h under Th2 differentiation conditions and
analyzed by flow cytometry. Generations of Th2 cells are in “red” and 4μ8c-treated cells are in “blue” in the histogram of cell proliferation
(left panel, one representative experiment). Graphical representation of division index as obtained from five independent biological
replicates (right panel)
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IL13-GFP, we observed the decrease in IL13 expres-
sion from the very first generation and this continues
throughout the later generations (Additional file 1:
Figure S9).
IRE1a inhibition delays cell cycle progression through the
S and G2/M phase
Bioinformatics analysis of differentially expressed genes
(Th2 vs 4μ8c-treated Th2) and XBP1 direct target genes
reveals several genes that are involved in controlling cell
cycle progression through different stages (i.e., G1, S,
G2/M) were clustered into two groups up- or downregu-
lated (Fig. 8a). We took genes differentially expressed in
4μ8c-treated Th2 compared to untreated Th2 (adjusted
p value < 0.05) (Fig. 8a, left, Additional file 9: Table S8)
and the genes differentially expressed XBP1 direct target
genes (Fig. 8a, right, Additional file 10: Table S9), and
checked for known roles across distinct cell cycle stages
using either a manually curated list based on RNA-seq
data or published database [53]. We found many genes
from all cell cycle stages (i.e., G1, S, and G2/M) were af-
fected. To identify the cell cycle stages regulated by
IRE1a-XBP1 pathway, we created and used a transgenic
FUCCI (fluorescent ubiquitin cell cycle indicator) mouse
strain that expresses mCherry-tagged Cdt1 and
mVenus-tagged Geminin protein. The strain is similar to
the one used in [31]. The G1 cells are mCherry+ mVe-
nus− (Q3; Fig. 8b), G1-S cells are mCherry+ mVenus+
(Q2; Fig. 8b), and SG2M are mCherry− mVenus+ (Q1;
Fig. 8b), while cells in mitosis and entering G1 are
mCherry− mVenus− (Q4; Fig. 8b). We compared cell
cycle profiles of vehicle and 4μ8c-treated Th2 cells dur-
ing T cell activation. We found that cells accumulated in
the S and/or G2/M phase when the IRE1a-XBP1 path-
way is blocked (Fig. 8b). Similar results were obtained in
a different approach using BrdU incorporation assay
with DAPI staining (Additional file 1: Figure S10).
Transgenic expression of XBP1s complements the 4μ8c-
mediated inhibition of IRE1a endonuclease activity
To test whether the observed 4μ8c-treated phenotypes
were due to the loss of XBP1s, we performed comple-
mentation assays by transducing a XBP1s expression
vector into the Th2 cells in vitro. The vector encoded
the spliced form of XBP1 (XBP1s), whose function is in-
dependent of IRE1a function. We found that stable ec-
topic expression of XBP1s negates the effect of 4μ8c
treatment and there is no significant change in the tran-
scriptome upon 4μ8c treatment when Th2 cells overex-
press XBP1s (Additional file 1: Figure S11A). XBP1s
overexpressing Th2 cells proliferate and differentiate
normally in presence of 4μ8c (Additional file 1: Figure
S11B and S11C respectively). These results strongly
suggest that the phenotypes observed upon 4μ8c treat-
ment are due to the loss of XBP1s.
Conclusions
The primary aim of this study was to investigate the role
of XBP1 transcription factor in Th2 lymphocytes and to
identify the Th2-specific XBP1 target genes and their in-
volvement regulating Th2 cell biology. We showed evi-
dence that the IRE1a-XBP1 pathway is engaged in
resolving secretory stress to meet robust cytokine syn-
thesis and secretion, and controls multiple important
cellular properties of T helper lymphocyte. It regulates
activation-dependent T helper cell proliferation and
cytokine production, the two key features of T helper
cell during activation. The study revealed a large tran-
scriptional regulatory network governed by XBP1. The
comprehensive repertoire of XBP1-regulated genes and
its genome-wide binding map provides a valuable re-
source for future work. We built a transcriptional regu-
latory map by integrating XBP1 ChIPmentation and
RNAseq data, which portrays the bigger picture of the
involvement of the XBP1 transcription factor in regulat-
ing target genes including other transcription factors. To
visualize the data, we created an easily browsable online
database available at http://data.teichlab.org.
ER-stress is known to be involved in several patho-
logical situations. The pathway promotes cancer pro-
gression by providing metabolic advantage to the
neoplastic cancer cells to acclimatize to the stressed
tumor microenvironment. During the anti-tumor im-
mune response, the XBP1 pathway induces tolerance in
DCs. The pathway promotes asthmatic, allergic, and eo-
sinophilic immune reactions and is involved in immuno-
metabolism of macrophages in obesity. The pathway can
be modulated by drug such as 4μ8c and STF-083010
and is under intensive investigation. Further studies will
have to be carried out to determine whether the modu-
lation of the pathway can bring patients’ benefit. This
study shows evidence that perturbation of the
IRE1a-XBP1 pathway may interfere with normal physio-
logical activation of Th2 and could be exploited in set-
tings where Th2 lymphocytes are pathologic such as
asthma, allergies, and eosinophilia. Two prominent
cytokines, IL5 and IL13, which promote allergies and
eosinophilia, are under the control of IRE1a-XBP1
pathway in Th2 lymphocytes. In future, locus-specific
mechanistic dissection of the XBP1-mediated tran-
scription process in Th2 lymphocytes and in vivo
immunobiological studies on novel Th2-specific XBP1
target genes are required to understand how the
XBP1 transcription factor orchestrates locus control
and to what extent it controls Th2-mediated immune
responses.
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Fig. 8 IRE1a inhibition delays cell cycle progression through the S and G2/M phase. a Left panel: heatmap of differentially expressed cell cycle
stage-associated genes in the 4μ8c-treated and untreated Th2 transcriptome. Right panel: heatmap of XBP1 direct target genes that are known to
be involved in cell cycling. The heatmap shows scaled expression values denoted as row Z-score, in red-blue color scale with red indicating
increased expression and blue indicating decreased expression. b Cell cycle analysis of Th2 lymphocytes after 72 h of activation, using FUCCI
mouse line that express mCherry-tagged CDT1 and Venus-tagged GEMININ. Upper left: diagrammatic representation of cell cycle stages in used
FUCCI mouse. Upper right: comparison of cells (% of total) obtained from different stages of cell cycle in Th2 and 4μ8c-treated Th2 (n = 6). Lower
panels: one representative FACS profile of Th2 and 4μ8c-treated Th2 showing CDT1 and GEMININ expressing cells
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